Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT01224262

A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001 (LIfT)

A Randomized, Observer-Blind, Controlled Phase 1/2a Study of the Safety, Tolerability and Immunogenicity of Fluzone Administered With and Without LIQ001 in Two Cohorts of Healthy Subjects: 18-49 Years of Age and 65 Years of Age or Older.

Sponsor: Accelovance

Conditions Influenza

Interventions Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) LIQ001 (0.45mg) LIQ001 (1.8mg)

Updated 7 times since 2017 Last updated: Feb 25, 2013 Started: Sep 30, 2010 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Influenza, this trial is completed. The trial is conducted by Accelovance and has accumulated 7 data snapshots since 2010. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Accelovance
Children's Hospital Medical Center, Cincinnati
Liquidia Technologies, Inc.

Data source: Liquidia Technologies, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, United States